Medicare GLP-1 Bridge Program to Launch for Weight Management

Beginning in July, Medicare beneficiaries will have access to GLP-1 medications through a new payment plan, offering a flat fee arrangement. This temporary endeavor, described by the Centers for Medicare and Medicaid Services (CMS) as a ‘time-limited demonstration,’ will operate from July 1, 2026, to December 31, 2027. Despite being close to its launch, specific details about its operation remain unresolved.

Program Overview

Announced in December, the program allows eligible Medicare Part D participants to obtain GLP-1 medications for a $50 monthly copay. While GLP-1 meds are indicated for diabetes, obesity, and some heart conditions, the Bridge program is primarily targeted at beneficiaries seeking weight management solutions, as current federal law prohibits Medicare from covering weight-loss drugs.

The initiative has garnered praise from advocacy groups such as the Obesity Care Advocacy Network (OCAN), with coordinator Cristy Gallagher highlighting its significance in combating obesity. There are concerns among regulatory observers, however, about the program’s administration costs. According to Stat News reporter Bob Herman, inquiries to CMS about the program’s budget have gone unanswered, and The Hill has sought similar information from the Department of Health and Human Services.

Operational Details

CMS states that enrollees need not complete additional paperwork once they have a prescription. To join, a provider must submit a prior authorization request alongside a prescription for an eligible GLP-1 medication, which includes Wegovy, Zepbound, and Foundayo. If a patient switches medications during the program, a new authorization form will be necessary.

A pharmacist will route the prescription to the Bridge program’s central processor, referred to as the Bridge PCN by CMS. CMS emphasizes that prospective authorizations will not be processed prior to July 1, ensuring prescriptions conform to specific health criteria before approval.

The Medicare GLP-1 Bridge seeks to test whether providing access at a uniform CMS negotiated net price will help improve outcomes and reduce long-term Medicare spending, said Kelly Strachan, CMS health insurance specialist.

The monthly copay will be separate from a beneficiary’s deductible and maximum out-of-pocket expenses.

Eligibility Criteria

Eligible beneficiaries must enroll in standalone prescription drug plans or Medicare Advantage coordinated care plans. CMS lists additional eligible groups, including those in Special Needs Plans, employer/union waiver plans, and the Limited Income Newly Eligible Transition program. Tricare For Life beneficiaries must also enroll in an eligible Part D plan type to participate.

Obesity medicine physician Catherine Varney explains that those at greatest risk of obesity-related diseases will benefit most. Requirements include a minimum BMI of 27, along with a diagnosis of conditions like prediabetes or heart-related issues. Those with a BMI of 35 or higher are eligible without additional diagnoses.

Regulatory Concerns

The program operates outside Medicare’s typical scope, as it offers medications for weight loss, which Medicare traditionally does not cover. Some experts worry this could create opportunities for fraud. Healthcare regulatory counsel Christopher Frisina suggests the program might draw new telehealth providers into Medicare reimbursements, with concerns about potential misuse.

Frisina mentions that CMS has established thorough authorization processes but acknowledges fraud risks exist. A comprehensive prior authorization form is required before approval, necessitating collaboration between providers and pharmacies.

CMS has not disclosed cost estimates or enrollment projections for the program. The $50 copay is separate from Part D benefit’s usual payment structure, according to CMS.